MAPT and Alzheimer disease: Tau-PET imaging (combined with CSF tau biomarkers in certain studies) has been able to predict future cognitive decline in cognitively unimpaired individuals, which could potentially increase screening efficiency in early-stage clinical trials for AD [76,77].